749-P: Tirzepatide as an Add-on for Participants with Inadequate Glycemic Control Using Basal Insulin—Pooled Subgroup Analysis of SURPASS-5 and -6

Introduction 65, ≥65 years), T2D duration (10, ≥10 years), and baseline (BL) HbA1c (≤8.5%, 8.5%). Data were pooled for SURPASS-5 and -6 up to Week 40. Results: Overall, 1072 participants were included. At BL, mean age was 59.3 years; 583 (54.4%) were female; mean T2D duration was 13.5 years; mean weight was 92.3 kg, mean HbA1c was 8.6%, and median insulin dose was 42 IU/day. For all subgroups, TZP treatment significantly reduced HbA1c and weight from BL to Week 40 without heterogeneity. Incidence of clinically significant hypoglycemia was numerically higher for participants in HbA1c 8.5% and T2D duration ≥10 years subgroups (Table). Conclusion: In this post hoc analysis of people with T2D and inadequate glycemic control with basal insulin with or without metformin, participants treated with TZP experienced significantly improved HbA1c and weight across different subgroups. Disclosure H.S. Bajaj: Research Support; Abbott, Amgen Inc., Anji Pharmaceuticals, Boehringer-Ingelheim, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer Inc. L.K. Billings: Advisory Panel; Novo Nordisk, Pfizer Inc. M. Liu: Consultant; Eli Lilly and Company. J.A. Levine: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. Á. Rodríguez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. H. Patel: None.